Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Tomas Navratil, the Chief Development Officer of Glaukos Corp (NYSE:GKOS), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. The transaction, executed on February 14, 2025, involved the sale of 3,416 shares at a price of $147.14 each, amounting to a total value of $502,630. The sale comes as Glaukos shares trade near their 52-week high of $163.71, having delivered a remarkable 65% return over the past year.
Following this sale, Navratil holds 72,437 shares of Glaukos, which includes 45,972 restricted stock units that have yet to vest. The sale was conducted under a pre-established Rule 10b5-1 trading plan, which Navratil adopted on November 12, 2024. With analyst price targets ranging from $120 to $200, InvestingPro data shows the company maintains strong revenue growth of 18.7% despite not being profitable in the last twelve months.
This transaction is part of regular insider trading activities that provide insight into the executive’s confidence in the company’s prospects. Investors often monitor such activities closely, as they can signal insider sentiment about the company’s future performance. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed research reports covering over 1,400 US stocks, including Glaukos.
In other recent news, Glaukos Corporation has reported promising developments regarding its iDose TR product, with clinical trials demonstrating sustained efficacy in reducing intraocular pressure in glaucoma patients over a 36-month period. The trials showed that 70% of subjects maintained controlled pressure levels with the same or fewer medications. Additionally, Glaukos has submitted a New Drug Application to the FDA for Epioxa, a non-invasive treatment for keratoconus, marking a significant step in offering less invasive options for eye disease treatment.
Analysts have shown a positive outlook on Glaukos, with Stifel raising its price target to $175 and maintaining a Buy rating, citing strong feedback from iDose-trained surgeons. Piper Sandler also increased its price target to $180, based on discussions with a glaucoma surgeon who views iDose as transformative in the field of minimally invasive glaucoma surgeries. Truist Securities reiterated a Buy rating with a $185 target, expressing confidence in the growth prospects of Glaukos’s iDose product.
These analyst updates reflect a shared belief in the potential for revenue growth and increased earnings due to the adoption of iDose. The company’s ongoing efforts, including the initiation of new clinical programs and the expansion of its product pipeline, suggest a robust strategy aimed at enhancing treatment options for chronic eye diseases. As Glaukos continues to advance its innovative treatments, the company remains a focal point for investment consideration among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.